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Abstract 
 
A common approach to treat respiratory diseases is with adhesive powder mixtures. 
These are dispersed into an aerosol upon inhalation. It has been found that the 
performance of such mixtures can be improved by adding fine particle lactose, but 
exactly why is yet to be established. Several theories have been proposed by previous 
studies, but the fundamental mechanism is still unknown.  
 
This study was done in order to examine the impact of lactose fines (LF) in adhesive 
mixtures. This was approached by manufacturing different formulations using a high 
shear mixer. The concentration of added fines was kept at a constant 8% for all batches, 
whereas the relative concentration between the active pharmaceutical ingredient (API) 
Beclomethasone Dipropionate (BDP) and LF was varied systematically. Two sets of 
formulations were made, one containing a force control additive (1% Magnesium 
Stearate), referred to as coated formulations, whereas the other contained no such 
additive, referred to standard formulations. Several samples were extracted at different 
time points during the mixing stage in order to get a better understanding on how the 
mixing process influences the dispersion properties. 
 
The aerodynamic particle size distributions of the API and LF were assessed using a Next 
Generation Impactor (NGI), which is a widely practiced technique within pharmaceutical 
development work. Quantification of BDP component was done using a well-developed 
method consisting of an ultra-performance liquid chromatography -system and an 
internal standard solution. However, this technique is not suitable to quantify the LF 
component. Overall, the analysis of lactose intended for inhalation is poorly described in 
literature. Therefore, one objective of this thesis was to find and evaluate such method. 
Two techniques were tried out; the first one being LC-PAD system based on 
electrochemical analysis. This was however disregarded due to instrumental errors and 
instead, a high pressure liquid chromotography system coupled with a mass 
spectrometer was used. However, this technique needs more tuning to be as good as 
the one used for BDP, as the assessed results did sometime display unreasonably high 
values and it is still unclear how much impact the carriers have on the analysis. 
 
Regarding the performance of the manufactured batches, it was observed that the Fine 
Particle Fraction (FPF) for the coated formulations were consistently higher than for the 
standard formulations, as was expected. The coated formulations did also show a 
dependency on the mixing process as regards the FPF values. No such effect could be 
seen for the standard formulations. It was also found that the FPF of LF were 
consistently higher than the FPF of BDP. The FPF of BDP was consistently higher for 
formulations with a higher amount of LF.  It was proposed that the LF and BDP form co-
agglomerates during mixing, which lies in agreement with one of the existing theories 
that explains the behavior of LF. 
 
  
3 
The NGI is, despite yielding high quality results, a rather time consuming method which 
bottlenecks the pharmaceutical development process. A faster method to assess the 
PSD of an adhesive mixture is by the usage of Laser Diffraction (LD). This technique is 
however chemically non-specific, which render analysis of adhesive mixtures including 
both LF and API a bit troublesome. It would be favorable for future work if there was a 
way of correcting for LF when analyzing using LD, and a second part of this thesis was 
thus to evaluate how well data assessed from the NGI correlated with data assessed 
with LD setups. 
 
It was found that it is possible to screen a formulation using LD if an appropriate 
dispersion method is used. However, in order to correct for LF in LD measurements, 
more research is needed as the LF seems to disperse differently in different 
formulations. Formulations with only LF as added fines correlated well with data 
assessed by the NGI. 
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List of abbreviations 
 
API    Active Pharmaceutical Ingredient 
BDP   Beclomethasone Dipropionate 
COPD   Chronic obstructive pulmonary disease  
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F5   Cumulative volume fraction <5 µm 
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FPF  Fine Particle Fraction 
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MMD   Mass Median Diameter 
MMAD  Mass Median Aerodynamic Diameter 
MS   Mass spectrometry 
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PSD   Particle size distribution 
RSD   Relative Standard Deviation 
TOF-SIMS  Time Of Flight – Secondary Ion Mass Spectroscopy  
UPLC   Ultra performance liquid chromatography 
 
 
  
6 
Table of Contents 
Abstract ............................................................................................................................... 2 
Acknowledgements ............................................................................................................. 4 
List of abbreviations ........................................................................................................... 5 
1. Introduction ..................................................................................................................... 7 
1.1 Theory ....................................................................................................................... 7 
1.2 Measuring adhesive mixtures ................................................................................. 11 
1.3 Aim of the study...................................................................................................... 14 
2. Materials and manufacturing ........................................................................................ 15 
2.1. Materials ................................................................................................................ 15 
2.2. Manufacturing of adhesive mixtures ..................................................................... 16 
3. Analytical methods ....................................................................................................... 18 
3.1 Next Generation Impactor....................................................................................... 18 
3.2. Liquid Chromotography......................................................................................... 19 
3.3 Laser diffraction measurements .............................................................................. 22 
 3.3.1 Sympatec RODOS .......................................................................................... 22 
 3.3.2 Sympatec Inhaler ............................................................................................ 22 
4. Results ........................................................................................................................... 24 
4.1 NGI ......................................................................................................................... 24 
 4.1.1. Formulations with MgSt ................................................................................ 24 
 4.1.2 Standard formulations .................................................................................... 31 
4.2 Laser diffraction ...................................................................................................... 35 
 4.2.1. Sympatec RODOS ......................................................................................... 35 
 4.2.2. Sympatec Inhaler ........................................................................................... 39 
4.3 Relaxation effect of formulations. .......................................................................... 44 
4.4 Effect of intrinsic fines. ........................................................................................... 45 
4.5 Images from scanning electron microscopy ........................................................... 46 
5. Discussion ..................................................................................................................... 49 
5.1 Behavior of the adhesive mixtures .......................................................................... 49 
 5.1.1 Effect of coating agent .................................................................................... 49 
 5.1.2 Influence of different mixing times ................................................................ 50 
  5.1.2.1 Mathematical modeling of FPF of BDP ................................................. 54 
 5.1.3. Effect of different concentrations between BDP and LF .............................. 56 
 5.1.4 Formation of agglomerates ............................................................................. 57 
5.2. Comparison between NGI and Laser Diffraction .................................................. 58 
6. Conclusions and further work. ...................................................................................... 65 
6.1 Conclusions ............................................................................................................. 65 
6.2 Further work............................................................................................................ 66 
7. References ..................................................................................................................... 68 
Appendix I – Raw data from measurements ..................................................................... 70 
Appendix II – Correlation plots ........................................................................................ 80 
 
  
7 
1. Introduction 
This thesis has been carried out in order to obtain fundamental understanding about the 
dispersion properties of powder formulations intended for inhalation. The focus has 
been in investigating the impact of adding fine particle lactose into such powder 
mixtures. This chapter will provide a brief background to the field, followed by a 
description of what was sought for when conducting this thesis.  
 
1.1 Theory 
Throughout history there have been several ways of treating different diseases, ranging 
from trepanation to phlebotomy, some methods better than others. One way, that even 
the old Greeks employed, was to inhale medicinal herbs into the lungs. Today, 
inhalation science is a well-established field of research and there are several 
pharmaceutical products on the market that employs the respiratory tract as a route of 
delivering medication. This has several advantages over oral or intravenous treatment 
including direct delivery to the target as well as rapid onset of drug action.  
Furthermore, systematic side effects are fewer as the dose can be smaller and unlike 
oral administration of the drug the lungs exhibit low metabolic activity. [1]  
When treating respiratory diseases, such as asthma or chronic obstructive pulmonary 
disease (COPD), the active pharmaceutical ingredient (API) is delivered to the lungs in 
the form of an aerosol cloud. An aerosol is defined as a two phase system of solid 
particles or liquid droplets dispersed in a gaseous phase such as air [2]. On entering the 
respiratory tract there are numerous ways that the inhaled particles can interact with 
the surrounding tissue, depending on their aerodynamic diameter. This is defined as the 
diameter of a unit-density sphere having the same settling velocity as the particle in 
question and is one of the most important properties of respirable particles [2].  
In order to reach the lower respiratory tract of the lungs, a generally accepted size 
interval for respirable particles is approximately between 1-5 µm (aerodynamic 
diameter), depending on the desired target site. Larger particles than this are likely to 
deposit earlier in the airway system and smaller particles are likely to be exhaled. [3] 
To deliver the particles to the targeted lung-regions there are different devices on the 
market that can be utilized, each one of them employing different techniques to create 
the aerosol cloud. A commonly used type is the Dry Powder Inhaler (DPI), in which the 
API is stored as a dry powder formulation. The driving force to create an aerosol from a 
static powder bed is the actuation generated by the patient´s inhalation effort, 
entraining the powder into the air flow. The dispersion is furthermore aided by the 
structure of the device. [4] 
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To achieve full dispersion of the powder, the formulation has to be carefully designed in 
order to overcome various difficulties respirable particles may experience. Particles of 
this size range are naturally cohesive due to their large surface area compared to mass, 
which leads to poor dispersion as well as poor handling properties of the powder within 
the DPI.  [4]   
To overcome these problems there are commonly two approaches employed. The first 
one is to form larger, loose agglomerates (defined as a system where primary particles 
of different sizes are held together by inter particulate contact forces) of the drug 
particles that are both easily broken and dispersed upon inhalation as well as more 
suitable to handle within the DPI. These agglomerates can also be made up by API and 
some inert excipient in the same size interval (typically 1-10 µm) to further ease de-
agglomeration upon inhalation. [5] A schematic view of this can be seen in Fig.1.1. 
 
Figure 1.1: A schematic view of agglomerates consisting of API and excipients that are dispersed 
upon inhalation. The arrow in the middle signifies the dispersion of the powder into an aerosol. The 
red spheres represent the API, where the blue spheres represent inert excipients. 
The other type of powder formulation intended for usage in a DPI is built up by a 
mixture of API particles along with coarser particles, referred to as carriers. These are 
typically 50-200 µm in diameter and consist of an inert material, often lactose 
monohydrate. The principle behind these mixtures is that the API will adhere to the 
surface of the carrier particles and upon inhalation, the API will liberate from the 
carriers and continue downwards the lower airways, while the carrier particles will 
deposit in the earlier stages of the lungs. [5] 
These kinds of mixtures, built up by coarse carriers and finer API-particles, are often 
referred to as adhesive or ordered mixtures. The carriers are generally less cohesive 
than the API and have better flow and fluidization properties, thus making these types 
of mixtures suitable to handle in a DPI[5]. A schematic view of the dispersion process for 
an adhesive mixture is shown in Fig 1.2. 
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Figure 1.2: A schematic view of API particles liberating from the surface of carriers upon inhalation. 
The arrow in the middle resembles the inhalation process which disperses the powder into an 
aerosol. The red spheres represent the API adhering to the carriers, which are shown as white 
blocks. 
The molecular forces responsible for the adhesion and separation between particles are 
mainly van der Waals forces and Columbic (electrostatic) forces, but also mechanical 
forces caused by surface roughness and irregularly shaped particles [6]  
If the adhesive forces between the API and the carrier are stronger than the inhalation 
forces induced upon inhalation, the API does not liberate from the carrier surface. By 
introducing a force control additive (FCA), also referred to as a coating agent, into an 
adhesive mixture it has been found that the adhesive forces between the API and 
carriers are reduced. It is believed that this additive is smeared onto the carriers or API 
particles as a thin layer, thus allowing for easier de-aggregation upon inhalation due to 
reduced van der Waals attractions. [7] 
To further improve the dispersion performance of an adhesive mixture it has been 
found that introduction of additional excipients within the same size range as the API 
can aid this cause. A commonly used material for this is lactose monohydrate. This 
excipient has been the focus of this thesis work and will hereby be referred to as lactose 
fines (LF). The mechanism of why the introduction of LF increases the dispersion 
performance of an adhesive mixture is still unknown, but different theoretical 
explanations have been proposed in literature. However, each of them has some 
drawbacks and further research is needed. 
A review by Jones et al. [8] refers to two main theories to explain the effect of LF: 
Active sites 
The surface of the carriers inhibits so called “active sites”, which are areas that are more 
adhesive than others. This results in a higher chance of smaller particles to adhere there 
first and the idea is that the LF saturates these sites, leaving the rest of the surface for 
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the API. The API adhere thus to less adhesive areas and are consequently more easily 
liberated from the carriers upon inhalation. 
Formation of agglomerates 
This theory states that instead of adhering to active sites, the finer particles (API and LF) 
form agglomerates during mixing. These agglomerates are then evenly distributed onto 
the carriers. Upon inhalation, these clusters are liberated from the carriers to be 
shattered and a higher dispersion of the API is achieved, compared to if the fines would 
adhere to the carriers alone. 
Furthermore, there is another, more recent theory, proposed by Shur et al. [9] to 
account for: 
 
Increased cohesion 
Formulations including fine lactose have shown to increase the cohesive strength of the 
bulk powder and by so, the minimum energy that is required for fluidization of the 
powder bed is increased and so is the energy available for dispersion. 
Another theory proposed by Dickhoff et al [10] is also found in literature: 
Fines acting as buffers 
During mixing, LF coarser than the API may protect the API from compression and act as 
a buffer between colliding particles. 
As stated previously, none of these theories are proven, but Kinnunen et al [11] suggests 
that the explanation might lie within a combination of these theories. 
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1.2 Measuring adhesive mixtures 
In order to study different formulations it is important to know the particle size 
distribution (PSD) of the aerosol cloud. There are different ways of assessing the PSD 
and a widely practiced technique is to use a cascade impactor, such as the Next 
Generation Impactor (NGI) shown in Fig. 1.3. 
  
Figure 1.3 : The image to the left displays an open NGI. The image to the right displays an NGI 
connected to a United States Pharmacopeia (USP) induction port and a pre-separator, mimicking the 
upper airways of the lungs. Typically a DPI is connected the inlet of the NGI, in which the powder is 
drawn from. In this work, a prototype device, described in chapter 3, was used. The airflow is lead 
from left to right, and the small cavities seen in the left figure fractionates the aerosol by impaction. 
[12, 13] 
The NGI is based on the principle that particles following an airstream will separate 
depending on their size and ability to adjust for sharp turns. Particles with high inertia 
will continue in their original direction and can thus impact on a collector plate, while 
smaller particles can follow the sudden change of the air stream. By coupling several 
collector plates in series and by letting the airstream pass through smaller and smaller 
nozzles thus increasing its speed, the aerosol can be fractionated according to the 
particles aerodynamic diameter.  
In the NGI the air flow is lead through a saw tooth pattern in a series of nozzles 
containing progressively reducing jet diameters. Different air flows give different cut-off 
diameters.  There are 8 stages of collector plates in the form of a removable tray that 
can be changed between each measurement.  The NGI typically gives a PSD interval of 
0.1 – 10 µm. [13] 
The NGI has 3 distinct advantages when it comes to measuring aerosols intended for 
respiratory medication; firstly, it gives the aerodynamic diameter of the particles, which 
is relevant for the intended deposition site in the lungs. Secondly, it gives the 
opportunity to analyze the collected particles with regards to their chemical 
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composition. Thus, the distribution of the API can be assessed; giving information on 
how much of the API that can reach down to the final stages of the lungs. Finally, it is a 
method approved by governments and it is described in various Pharmacopeias. 
However, drawbacks with this method is the long analysis times and high labor 
consumption, which easily can bottleneck the pharmaceutical development process.  
Another way of assessing the PSD of an aerosol is by the usage of laser diffraction (LD). 
The aerosol passes through a laser beam and the particles will then, depending on their 
size and refractive index, scatter the beam differently.  
 
  
Figure 1.4: A schematic view on how the light scatters differently depending on the particle size. 
Displayed to the right is the diffraction pattern of smaller respectively large particles. By courtesy of 
Patrik Andersson [14] 
A fourier lens is used to focus the scattered light onto a detector. With the help of 
computational power the PSD can be calculated from the acquired signal, using existing 
mathematical theories and assumptions (Mie and Fraunhaufer) [14]. A typical PSD 
interval using LD is 0.5 - 200 µm but this depends on the lens used in the measurement. 
[14] 
The LD provides a fast and cheap screening method in comparison to the NGI, but it 
comes with some drawbacks. Firstly, the technique cannot differentiate between 
different chemical components such as the API and other excipients. Secondly, it 
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measures the geometrical diameter and thirdly, the mathematical calculations assume 
spherical particles which rarely are the case for ordered mixtures.  
By knowing the PSD of a formulation, the amount of API that reaches the intended 
regions in the lungs can be evaluated. Using the NGI, the fine particle fraction (FPF) is 
commonly sought for. This is defined as the fraction of particles of the total API-dose 
below a set cut-off value (usually 5 µm). Another important value given from the PSD is 
the mass median diameter (MMD) which is defined as the diameter at which 50% of the 
particles by mass are larger and 50% are smaller. For aerodynamic particles, which are 
relevant for inhalation, the mass median aerodynamic diameter (MMAD) is used. [2]. 
The FPF equivalent for LD is Cumulative Volume Fraction < 5 µm (here denoted as F5). 
Note that this value may include both API and excipients, such as LF, since the method 
cannot differentiate between different compounds. In this work the LD equivalent to 
MMAD is referred to as Fine Particle mode (FPmode), which is the peak value of fraction 
of finer particles, shown in Fig. 1.5. 
 
  
Figure 1.5: The left image displays a typical PSD from laser diffraction measurement and the right 
image resembles a zoomed in view of the particles below 5 µm. From this the FPmode can be 
assessed, shown by the arrow. 
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1.3 Aim of the study 
The aim of this thesis was to obtain further understanding of the behavior and effect of 
LF within an adhesive powder mixture. This was targeted by manufacturing several 
formulations containing different amount of LF and API. The analysis work was 
constructed around two main objectives, where the first involved measurements using 
the standard method NGI. For this part the following topics were dealt with: 
 How does LF behave in different formulations and how do they affect the 
performance of the API? 
 How are adhesive mixtures with API and LF influenced by different processing 
times? 
 How does addition of a coating agent affect the formulations? 
  
As LD measurements provides a faster screening of formulations compared to the NGI, 
it would be beneficial for future development if there is a way to correct for LF when 
evaluating the performance of an API. Therefore, the other main objective for this thesis 
was to compare results given by the NGI with results given by LD measurements with 
the following question in mind:  
 Is there a way to correct for LF using LD method, in order to predict the FPF of 
the API?  
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2. Materials and manufacturing 
This work included manufacturing of adhesive mixtures, divided into two sets of mixing. 
In the following sections the materials that were used are presented, followed by a 
description of the manufacturing processes. 
2.1. Materials 
The carrier in the formulations was an inhalable form of lactose, Respitose SV003, with 
an intrinsic amount of fines of roughly 1 %.  The term intrinsic fines refer to finer 
particles inherent from the production process. The API was micronized 
Beclomethasone Dipropionate (BDP), which is a glucocorticoid steroid with anti-
inflammatory properties. The LF were micronized and conditioned lactose, where 
conditioning refers to re-crystallization of amorphous regions formed during 
micronisation. For the first set of mixing Magnesium Stearate (MgSt) was added as a 
coating agent. For the second set no such coating additive was present. The different 
formulations will be referred to as coated formulations and standard formulations, 
respectively. 
The total amount of added fine particle (API and LF) was set to 8 wt% for all 
formulations, as it has been observed that the concentration of total fines relates to the 
performance of an adhesive mixture [15], where 8% lies within the region of neither 
being too much nor little.  
An overview on the materials used for manufacturing in this work is presented in table 
2.1. and in table 2.2 the relative weight concentrations are given. 
Table 2.1. List of raw material used in this work. 
Material Batch# MMD (µm) Supplier 
Carrier 
Lactose, Respitose SV003 
 
 
1301 
 
60.0* 
 
DFE Pharma 
Coating agent 
Magnesium Stearate 
 
 
30003501 
 
5.0* 
 
Peter Greven 
API and fines 
Beclomethasone Dipropionate, Micr. 
 
Lactose, Micr. and cond. 
 
 
03220520 
 
309001 
 
1.3* 
 
2.4* 
 
Meridian 
Pharmaceuticals Inc. 
AstraZeneca 
* Measured at AstraZeneca 
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2.2. Manufacturing of adhesive mixtures 
Production and mixing of the formulations were done using a Diosna P1-6 high shear 
mixer equipped with a mixing vessel of 1.2 liter made of stainless steel, displayed in Fig. 
2.1. The speed of the mixing blade was set to 800 rpm and the mixing was performed 
inside an isolator-box to avoid contact with the drug. The relative humidity of the 
isolator box was set to around 20 % and the temperature was around 22o C. Between 
each mixing of a batch the isolator box including the mixing vessel was dry cleaned using 
a vacuum hose.  
 
Figure 2.1: An image of the high shear mixer used in this work, Diosna P1-6 [16]. 
8 sets of formulations were manufactured, divided into two sets of mixing, with a total 
mixing time of 120 minutes for each batch. The mixing was stopped 8 times at different 
time points for sampling and thus a total of 9 samples were extracted from each batch, 
including the end-point. The specific time points where the blending was stopped was 2, 
5, 10, 20, 30, 45, 60, 90 and finally 120 minutes for all batches. The extracted samples 
were roughly 25 grams each and the total amount of material for each batch was 350 
gram.  
In the first set of mixing, a pre-coating step of the carrier was performed. Half of the 
carrier was added evenly into the mixing vessel, followed by the MgSt and then the rest 
of the carriers. This pre-blending step was done at 70 rpm for 2 minutes and 350 rpm for 
1 minute, followed by 10 minutes of mixing at 800 rpm. This was done in order to smear 
out the MgSt on the carrier surface. The LF and API were then added layer-wise and 
mixed for 2 min at 70 rpm and 1 min at 350 rpm before the mixing at full speed of 800 
rpm was started. The conditions for second set of mixing were the same as for the first 
mixing set, but without the coating step. The components were added layer wise, 
starting with half of the carrier followed by API and LF and then the rest of the carrier.  
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Table 2.2. List of the weight concentration of each component in the manufactured batches. 
Coated formulations 
 
Batch# Carriers LF BDP MgSt Yield  
EB14-
032125 
 
91 % 8% 
 
0% 1% 87,4% 
EB14-
032126 
 
91 % 
 
6% 2% 1% 86,8% 
 
EB14-
032127 
 
91 % 4% 4% 1% 87,4% 
 
EB14-
032128 
 
91 % 2% 6% 1% 83,1% 
 
EB14-
032129 
 
91 % 0% 8% 1% 84,7% 
 
 
 
Standard formulations 
 
EB14-
023132 
 
92 % 8% 
 
0% - 56,6% 
 
EB14-
023133 
 
92 % 
 
6% 2% - 91,3% 
 
EB14-
023134 
 
92 % 4% 4% - 95,7% 
 
 
 
The 120 min sample from the 8% LF mixture was unfortunately exposed to water when 
emptying the mixing bowl (due to residual water that had been left in cooling pipes of 
the mixing vessel after the previous cleaning) and thus damaged. Therefore, no analysis 
of this point could be made. 
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3. Analytical methods 
A variety of different techniques and measurement instruments were employed 
throughout this work. In the following chapter a description of these will be given 
followed by the settings and conditions applied in each measurement. 
3.1 Next Generation Impactor 
To acquire the FPF of the formulations an NGI was used. A prototype inhaler device, 
referred to as screenhaler and displayed in Fig 3.1, was fitted to the USP throat of the 
NGI. 
 
Figure 3.1: A schematic view [15] of the device, referred to as screenhaler, used during NGI 
measurements. The screenhaler is a rather simple device with no inherent deaggregation 
mechanism, where the dispersion of the powder relies basically on the applied airflow. The device 
consists of L-shaped cylindrical channel with a diameter of 7 mm made of stainless steel. 
The powder was weighted into the screenhaler using a spatula. An airstream through 
the impactor was created by using a trig box, giving a defined air flow rate and a fixed 
measurement time, connected at the end of the impactor. 
A pre-separator was connected between the USP throat and the impactor-body. 
Standard settings for measurements were applied, where the pressure drop was set to 
1.5 kPa, the measurement time was set to 3.1 s and the flow rate was set to 77 lpm. 
Impactor plates were coated with a Brij-solution in prior to each measurement in order 
to reduce bounce off effects. Each measurement consisted of a total of three doses of 
roughly 5 mg of formulation / dose. In Fig 3.2 the cut-off sizes for the flow used in NGI 
measurement can be seen along with the PSD of an API within an adhesive mixture 
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Figure 3.2: Deposition curve within the NGI for coated formulation containing 2% BDP and 6% LF. 
The cut-off values for the used airflow are given on the X-axis. 
After each measurement, the NGI was dissembled. The throat and pre-separator was 
filled with appropriate solution (depending on type of fine particles being examined, see 
section 3.2 below) and covered up to be put in a rotating setup for 15 min in order to 
dissolve the excipients for chemical analysis. The impactor plates were filled with 
appropriate solution and put on a rotating table for 15 minutes at 50 rpm.  
3.2. Liquid Chromotography 
Chemical analyses of the impactor plates were done by using Liquid Chromotography, 
which is a widely used technique for analytical measurements of components in a 
sample mixture. The mixture, which consists of a solvent and the analytes, is passed 
with the help of a pump through a column filled with adsorbents of typically very fine 
particles (1.5-2 µm). Depending on the nature of each analyte, they will interact 
differently with the column, leading to a separation of the components once they exit 
the column. Depending on the analytes, elution times will be different and they can be 
separated from each other. By having an internal standard of known concentration in 
the mixture, the unknown analyte can be quantified. A schematic view of a 
chromatogram can be seen in Fig. 3.3. The BDP and LF components were in this work 
analyzed separately. 
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Figure 3.3: A schematic view of a chromatogram acquired for one of the samples, where the BDP 
component was analyzed. The first peak resembles the internal standard and the second peak 
resembles the amount of BDP. The area beneath a peak corresponds to the amount and since the 
internal standard is known, the amount of BDP in each step can be calculated. This was done for 
each step of the NGI in order to get the PSD of the API. 
Chemical analysis of BDP was done by using a standard method relying on Liquid 
Chromatography (LC) coupled with an UV-detector. An internal standard (IS) solution 
was used for quantification of the BDP for each impactor plate. The IS consisted of 40 
mg fluocinolone acetonide (reference substance) per 1000 ml of ethanol, which was 
used to dissolve the BDP in the different stages of the impactor. An amount of 20 ml 
was used at each step and when the BDP was dissolved completely, an amount of 0.5 ml 
from each step was transferred using a plastic pipette into an LC glass vial. Prior to this 
step the vials were filled with 0.7 ml buffert solution with a pH 3.2, consisting of 3.17 
sodium dihydrogen and 0.23 g orthophosphoric acid per 1000 ml of de-ionized water. 
The vials were then analysed using Ultra Performance Liquid Chromatography (UPLC), 
giving the amount of BDP in each step of the NGI.  
To assess the FPF of the LF component the same technique used for BDP could not be 
applied since lactose has no chromophores. Analysis of lactose intended for inhalation is 
overall vaguely described in literature. Some studies have done some attempts of doing 
so [17] but it has not been a major focus of the overall research. Thus, a part of this 
thesis was to find and evaluate such method.  
The original idea was to try and analyze the LF using a LC-PAD method, which is based 
on reduction and oxidation potentials. But, due to malfunctioning instrument and long 
repair-time that idea had to be altered. Instead, an alternative method residing in mass-
spectrometry was chosen.   
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To get the FPF of the lactose component a High-Pressure Liquid Chromatography) –
system (HPLC) was used coupled with a MS detector. The principle behind MS is that the 
sample is vaporized and ionized, then sorted and counted through an electrical field, 
giving the amount of the analyte in the sample. Since this technique is not extensively 
used for this purpose, some method evaluation had to be done before the analysis of 
lactose in the formulations could start. Samples with known amount of lactose were 
made in order to find a linear detector region of the MS, as well as a comparison 
between LC-PAD and MS data which gave adequate correlations. The detection region 
finally used was set to 1 - 8 µg / ml. 
Unlike the determination of BDP, where an internal standard could be used to quantify 
the amount of BDP in each LC vial, no such method could be applied for analyzing the 
amount of LF Instead, an amount of 15 ml purified and de-ionized water was used to 
dissolve the lactose in each NGI-step (apart from the pre-seperator, where a total of 30 
ml of water was used). By knowing the exact amount of added water, the amount of 
lactose in each step could be calculated from the results of the measurement.  
However, at first when running these samples the amount of lactose was too high and 
outside the linear detection region. Adjustments were made by diluting the throat-piece 
and pre-separator 100 times and impactor plates 1-5 10 times.  
Since the mass-spectrometry were both more time consuming when running the HPLC-
system (compared to the UPLC-system used for BDP analysis) and had a more limited 
access, it was decided to only take 1 replicate of the samples from the coated 
formulations and instead run all mixing times (apart for the 2 minute sample). To 
confirm that the mass-spectrometry method gave adequate results, the amount of 
powder loaded into the screenhaler was weighted before each run to see if reasonable 
amounts could be traced back.  
However, for some data-points the results were flawed. For example, the detected 
amount of lactose was more than what was weighted in. Therefore, new replicates were 
taken for these time points, which gave results in agreement with the other data. 
Once the data from the LC analysis was collected, an in-house developed excel 
template, based on statistical methods, was used to assess the FPF and MMAD values 
for the BDP and LF in each sample. 
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3.3 Laser diffraction measurements  
The laser diffraction measurements were conducted using a Sympatec Helos instrument 
with two different setups, which will be described in the following sections.  
3.3.1 Sympatec RODOS 
The RODOS setup is an automated dispersion unit, displayed in Fig. 3.4, which operates 
at air pressures ranging from 0.1 bar to 6 bar. It has a strong dispersion mechanism, 
created by using compressed air to push the sample powder through an injector. 
The powder was filled into a small glass vial and inserted into a chamber connected with 
a vacuum. A pressure of 4 bar was then applied and the powder was dispersed into an 
aerosol passing through the laser beam. This pressure is considered to fully disperse the 
sample powder. The feed rate of the glass vial into the chamber was set to 25 mm/s. 5 
replicates were taken for every sample. All mixing times were investigated. A 
background reference measurement was taken prior to each new batch. The system 
was rinsed with lactose carriers between each batch in order to remove fine particles 
getting caught to the inner walls of the setup. 
 
Figure 3.4: A schematic view of the RODOS setup [18]  
3.3.2 Sympatec Inhaler 
The second setup of the LD system was an AstraZeneca in-house developed method, see 
Fig 3.5.  The setup consisted of a metal tube, made from copper with an inner diameter 
of 8.4 mm, aligned towards the measuring chamber. The sample was put into this tube 
and flushed out through the laser beam using pressurized air. Two different air flows 
were investigated; 50 lpm and 100 lpm respectively.   
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Figure 3.5: The Inhaler setup. The upper arrow points towards the measurement chamber. The lower 
arrow points towards the tube in which the powder was put into. 
All mixing times were investigated and 6 replicates were taken for each sample. 
Between every measurement the tube was flushed three times using pressurized air and 
for every third sample the tube was rinsed with lactose carriers, in order to remove 
possible excess particles adhering to the inner walls. A background measurement was 
taken prior to each new batch. 
 
Whereas the settings applied in the RODOS system is considered to disperse the sample 
powder fully, the inhaler setup is more alike that of the NGI and the conditions thus 
more relevant to a patient inhalation. The employed air flow is within the same range as 
the NGI and the dispersion tube resembles the screenhaler-device used in the NGI 
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4. Results 
In this chapter the results from all of the experimental work and measurements will be 
presented. They will be presented in the order of method they were acquired with, 
divided into formulations coated with MgSt followed by standard formulations. When 
present, the error bars in the graphs represent standard deviation amongst replicates. 
The raw data from the measurements are presented in Appendix I. 
4.1 NGI 
In the following section the data from the NGI measurements will be presented. As the 
different components (BDP and lactose) were analyzed separately they will be 
presented as such. Note that for all batches the total amount of added finer particles is 
always 8%. For example, 2% BDP in Fig. 4.1 refers to an analysis of the BDP component 
in a batch containing 2% BDP and 6% LF. Likewise, 2% LF in Fig. 4.7, refers to analysis of 
the lactose component in a batch containing 2% LF and 6% BDP. 
Data are presented in terms of FPF and MMAD as a function of mixing time. An in-house 
developed excel template was used to determine these values by inserting the 
aerodynamic PSD data from the impactor measurements. 
4.1.1. Formulations with MgSt 
Results from BDP-measurements: 
Fig.s 4.1-4.4 show how the FPF of the BDP component for the coated formulations is 
influenced by the manufacturing process, in terms of different mixing times. The data 
shows an increase of FPF as mixing time increases, until it at a certain point reaches a 
maximum. Subsequently, the FPF declines as the mixing time increases further. This is 
consistent for all batches and the maximum of the FPF is obtained for the 30 minute 
sample of the mixing process. 
The ratio between BDP and LF influences the value of the maximum FPF; the highest FPF 
is for the batch with the lowest amount of BDP. As can be seen in Fig. 4.5 the maximum 
FPF is steadily declining the more BDP that the formulation contains. Furthermore, the 
larger amount of BDP, the less is the difference between maxima and minima points, 
resulting in a more flat curvature. 
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Figure 4.1: Fine Particle Fraction of BDP obtained from impactor analysis of formulation containing 
2% BDP and 6% LF, as a function of mixing time. The values represent mean values of 2 replicates 
and the error bars shows the standard deviation. 
 
Figure 4.2: Fine Particle Fraction of BDP obtained from impactor analysis of formulation containing 
4% BDP and 4% LF, as a function of mixing time. The values represent mean values of 2 replicates 
and the error bars shows the standard deviation. 
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Figure 4.3:  Fine Particle Fraction of BDP obtained from impactor analysis of formulation containing 
6% BDP and 2% LF, as a function of mixing time. The values represent mean values of 2 replicates 
and the error bars shows the standard deviation. 
 
Figure 4.4: Fine Particle Fraction of BDP obtained from impactor analysis of formulation containing 
8% BDP and 0% LF, as a function of mixing time. The values represent mean values of 2 replicates 
and the error bars shows the standard deviation.  
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Figure 4.5: Fine Particle Fraction of the BDP component obtained from impactor analysis of the 30 
minute samples, as a function of concentration of BPD. The values represent mean values of 2 
replicates and the error bars shows the standard deviation. 
In Fig. 4.6 the MMAD of BDP is plotted as a function of mixing time. It can be found that 
the value of MMAD is the lowest where the FPF is the highest.  
 
Figure 4.6: Mass Median Aerodynamic Diameter of BDP as a function of mixing time. The values 
represent mean values of 2 replicates and the error bars shows the standard deviation. 
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Results from lactose measurements: 
Fig.s 4.7 - 4.10 show how the FPF of the lactose varies for different mixing times. Note 
that since the lactose includes the carriers as well, the FPF results are much lower than 
that of BDP. The maximum value of the Y-axis is the total amount of added LF. 
Compared to the curvature of BDP, the LF curves are much flatter and it is not as easy to 
distinguish a maximum value in FPF. However, for the batch containing 8% LF there 
seems to be a decrease of FPF as mixing time increases, except for the 120 minute 
point, which show an increase.   
No error bars are presented as only one replicate was taken, as stated in section 3.2.  
 
 
Figure 4.7: Fine Particle Fraction of lactose obtained from impactor analysis of formulation 
containing 2% LF and 6% BDP, as a function of mixing time. 
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Figure 4.8: Fine Particle Fraction of lactose obtained from impactor analysis of formulation 
containing 4% LF and 4% BDP, as a function of mixing time. 
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Figure 4.9: Fine Particle Fraction of lactose obtained from impactor analysis of 
formulation containing 6% LF and 2% BDP, as a function of mixing time. 
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Figure 4.10: Fine Particle Fraction of lactose obtained from impactor analysis of formulation 
containing 8% LF and 0% BDP, as a function of mixing time. 
In Fig. 4.11 the MMAD of the fine lactose component is plotted against mixing time. It is 
consistently higher than that of BDP. Note that the MMAD evaluation is more difficult 
for LF, since the carrier particles influences the MMAD evaluation within the excel 
template. This result in some samples having values above the validated range of 
MMAD determination. 
 
Figure 4.11: Mass Median Aerodynamic Diameter as a function of mixing time for lactose. The values 
following the 45 minute sample of the batch containing 2% LF are omitted, due to high values above 
the validated range for MMAD determination. 
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4.1.2 Standard formulations 
In this section the results from the second series of mixing, referred to as standard 
formulations, will be presented. A narrowed amount of batches were manufactured, 
leaving out the relationships of 2 + 6 and 6 + 2 between the LF and BDP.  
Results from BDP-measurements: 
Overall, the values of FPF are much lower for these formulations compared to the 
coated batches. Furthermore, the mixing time seem to have less influence on the FPF as 
well, as the difference in maxima and minima points is much lower than before. 
However, the batch with 4% BDP and 4% LF has a higher FPF than the batch with 8% 
BDP and 0% LF. It is hard to determine any clear maximum point for both batches, but 
the batch with 8% BDP seems to have the maximum shifted towards higher mixing 
times. Though, that might be due to errors that lie within the measurement technique. 
 
Figure 4.12: Fine Particle Fraction of BDP obtained from impactor analysis of formulation containing 
4% BDP and 4% LF, as a function of mixing time. The values represent mean values of 2 replicates 
and the error bars shows the standard deviation. 
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Figure 4.13: Fine Particle Fraction of BDP obtained from impactor analysis of formulation containing 
8% BDP and 0% LF, as a function of mixing time. The values represent mean values of 2 replicates 
and the error bars shows the standard deviation. 
Regarding the MMAD values, shown in Fig. 4.14, the 8% BDP seems to have a minimum 
at 60 min, which would correlate to a maximum of FPF at the same time point. The 4% 
BDP is showing a steady increase of MMAD over time. Both batches have a consistently 
higher MMAD compared to the coated formulations, for all mixing times.  
 
Figure 4.14: Mass Median Aerodynamic Diameter of BDP as a function of mixing time. The values 
represent mean values of 2 replicates and the error bars shows the standard deviation. 
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Results from lactose measurements: 
As well as for the BDP, the FPF of lactose are lower for the uncoated formulations, see 
Fig.s 4.15-4.16. For the batch containing 4% LF and 4% BDP, the flat curvature however 
remains, as is the case of the decreasing curve for 8% LF. The 120 minute sample of 8% 
LF was unfortunately damaged during the manufacturing process, making a comparison 
between the coated and the standard formulations more troublesome.  
 
Figure 4.15: Fine Particle Fraction of lactose as a function of mixing time for batch containing 4% LF 
and 4% BDP. Note that the 20 min bar represents only one sample, due to the other replicate having 
an unrealistic value of over 5 % which is more than 100% of the added LF. Therefore, that point was 
omitted from the figure. The values represent mean values of 2 replicates and the error bars shows 
the standard deviation. 
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Figure 4.16: Fine Particle Fraction of lactose obtained from impactor analysis of formulation 
containing 8% LF and 0% BDP, as a function of mixing time. The values represent mean values of 2 
replicates and the error bars shows the standard deviation. 
The lactose MMAD values, which can be seen in Fig. 4.17, approaches the limit where 
the evaluations are no longer valid. The graph should only be interpreted as the MMAD 
for LF is larger for the standard formulations than for the coated formulations as well as 
not being influenced much by the mixing process. 
 
 
Figure 4.17: Mass Median Aerodynamic Diameter as a function of mixing time for lactose. The values 
represent mean values of 2 replicates and the error bars shows the standard deviation. 
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4.2 Laser diffraction 
In the following section the results from the different laser diffraction setups will be 
presented. As two different set ups were used they will be presented separately, 
starting with the RODOS setup followed by the Inhaler setup. The results will be 
presented as F5 and FPmode. Since laser diffraction cannot distinguish between different 
materials, the results will be including both the lactose and BDP components combined. 
4.2.1. Sympatec RODOS 
The Sympatec RODOS setup can in this work be considered as a maximum dispersion 
reference for the formulations, as the dispersion pressure is significantly higher 
compared to both the NGI and Sympatec Inhaler setup.  
Coated formulations 
In Fig. 4.18, F5 is presented for all batches. As was the case for the NGI, a maximum 
point can be seen for almost all formulations, with the 8% LF batch as an exception. 
However, the maxima occur much earlier into the mixing process, as well as the 
decrease in F5 is greater than for the FPF of the NGI curves. The batch containing the 
highest amount of BDP (8% BDP and 0% LF) shows the highest value of F5 and as the 
amount of BDP decreases, so does the fraction <5 µm.  
Regarding the 8% LF batch, no maxima point is seen and F5 decreases as the mixing time 
increases. However, surprisingly for all batches is that into 120 minutes of the mixing 
process they all seem to gather at the same point, giving approximately the same value. 
If this is due to some physical principle or simply just a coincidence can only be 
speculated based on these data. 
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Figure 4.18: Cumulative volume fraction < 5 µm for formulations coated with MgSt, assessed with 
Sympatec RODOS at 4 bar dispersing pressure. The values represent mean values of 5 replicates 
and the error bars shows the standard deviation. 
Regarding the FPmode, see Fig.4.19, there are some things to be noticed. Batches with 
the highest amount of BDP (8% and 6% respectively) and the 8% LF batch, are both 
rather flat and aren’t influenced much by the mixing process.  
However, the 2%BDP / 6% LF batch has a similar curvature as the same batch measured 
with the NGI, with a minima point slightly shifted towards an earlier mixing time.  
The curvature for 4% BDP / 4% LF are at the beginning flat, with an increase at 60 
minutes into the mixing process. 
It can be noted that the values on the Y-axis are higher than that of the added total 
amount of fines. This is due to the fact that the mathematical calculations and 
simplifications leads to an overestimation of finer particles within the formulations, as 
stated in section 1.2.  
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Figure 4.19: Fine Particle mode for formulations coated with MgSt, assessed with the Sympatec 
RODOS at 4 bar dispersing pressure. The values represent mean values of 5 replicates. 
Standard formulations 
In Fig. 4.20 the F5 for standard formulations measured in RODOS at 4 bar is presented. However, 
these data are likely to be faulty, as it was discovered that the measurement times exceeded the 
normal measurement times greatly (10s instead of 0.5s). This was seen as a build-up effect, 
where the first replicate showed normal measuring times but as the measurements progressed, 
the measurement time increased. This might be due to finer particles adhering to the inner walls 
of the setup, which after sub-sequent measurements starts to liberate and thus disturbs the 
measurement. It was seen that the measurement time decreased to normal values after rinsing 
the system. This was clearly seen after the 20 minute sample of the 8% LF formulation.  After 
this point the measurement time went up and cannot be considered trustworthy. 
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Figure 4.20: Cumulative volume fraction < 5 µm for standard formulations, assessed with Sympatec 
RODOS at 4 bar dispersing pressure. The values represent mean values of 5 replicates and the error 
bars shows the standard deviation. 
 
 
Figure 4.21: Fine Particle mode for standard formulations, assessed with the Sympatec RODOS at 4 
bar dispersing pressure. The values represent mean values of 5 replicates. 
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4.2.2. Sympatec Inhaler 
The Sympatec Inhaler instrument is a more patient relevant set up than RODOS, as the 
air flow are more alike the ones in a general DPI.  
Coated formulations 
In Fig. 4.22 and 4.23 the F5 is presented for 50 lpm and 100 lpm, respectively. The 
standard deviations are rather large for all batches, but common for both graphs is the 
behavior of respective formulation. For all batches except 8% LF, they follow, more or 
less, the same curvature as for the NGI results with a maxima point in the mixing 
process. The 8% LF batch seems to show a decline in F5 as mixing time increases.  
Fig. 4.22 shows a lower F5 for all batches, as is expected when a lower dispersion flow is 
used. 
 
 
Figure 4.22: Cumulative volume fraction < 5 µm for formulations coated with MgSt, assessed using 
Sympatec Inhaler at 50 lpm. The values represent mean values of 6 replicates and the error bars 
shows the standard deviation. 
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Figure 4.23: Cumulative volume fraction < 5 µm for formulations coated with MgSt assessed using 
Sympatec Inhaler at 100 lpm. The values represent mean values of 6 replicates and the error bars 
shows the standard deviation. 
 
Considering the FPmode, Fig. 4.24 presents the result from the measurements done 
with a flow of 50 lpm. All batches, except 8% BDP, shows a sudden increase of particle 
size in the beginning of the mixing process, but as the mixing time increases they all 
flattens out at approximately the same value. The behavior of the 8% BDP batch is more 
or less the same, but with a not as sudden increase in the beginning.  
 
By increasing the air flow to 100 lpm, the particle size of the FPmode decreases as can 
be seen in Fig. 4.25. The end points of the relative concentrations (8% BDP +0% LF and 
0% BDP + 8% LF) shows a rather flat curvature, while the other batches have the same 
look (more or less) as the NGI curves, with a minima point somewhere in the mixing 
process. 
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Figure 4.24: Fine Particle mode for formulations coated with MgSt assessed with the Sympatec 
Inhaler setup at 50 lpm. The values represent mean values of 6 replicates. 
 
 
Figure 4.25: Fine Particle mode for formulations coated with MgSt assessed with the Sympatec 
Inhaler setup at 100 lpm. The values represent mean values of 6 replicates. 
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Standard formulations 
The standard formulations show a rather flat curvature considering the F5, as presented 
in Fig. 4.26 and 4.27. A small decrease in the beginning of the mixing process can be 
seen for 4% BDP + 4% LF and 8% BDP. The air pressure does not seem to influence the 
appearances of the curves, apart from giving a higher fraction <5 µm for the higher air 
flow. 
 
Figure 4.25: Cumulative volume fraction < 5 µm for standard formulations, assessed with the 
Sympatec Inhaler  setup at 50 lpm. The values represent mean values of 6 replicates and the error 
bars shows the standard deviation. 
 
Figure 4.26: Cumulative volume fraction < 5 µm for standard formulations, assessed with the 
Sympatec Inhaler  setup at 100 lpm. The values represent mean values of 6 replicates and the error 
bars shows the standard deviation. 
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As it goes for the FPmode of the standard formulations, these curves are as well rather 
flat and the particle sizes are larger for the lower air pressure. Note that no data from 
the 8% BDP could be obtained as no FPmode could be distinguished from the PSD. 
 
Figure 4.27: Fine Particle mode for standard formulations assessed with the Sympatec Inhaler setup 
at 50 lpm. The values represent mean values of 6 replicates. 
 
Figure 2.28: Fine Particle mode for standard formulations assessed with the Sympatec Inhaler setup 
at 50 lpm. The values represent mean values of 6 replicates. 
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4.3 Relaxation effect of formulations. 
When analyzing the FPF of the BDP component in the coated formulations a, to some 
degree, unexpected effect was observed. The initial measurements displayed a 
maximum FPF of the BDP at 30 minutes of mixing, which was consistent for all 
formulations. The 45 min samples were thus analyzed to see if there would be a shift in 
the maximum FPF. Along with these measurements, the 20 and 30 minute samples of 
coated formulations with 8% BDP were analyzed anew in order to confirm that they 
would give the same results as previously measurements. However, the FPF was higher 
than previously, showing that the FPF had increased over time. These results are 
displayed in Fig. 4.29.  
A speculative explanation to this can be that electrostatic forces induced upon mixing 
equilibrates over time, thus allowing for a less strong attraction between API and carrier 
which would results in a better dispersion, thus a higher FPF. However, the time limit of 
this work prohibited further investigation on this matter and therefor these results will 
not be considered further when discussing the results.  
 
Figure 4.29: Effect of storage time for coated formulation with 8% BDP. The FPF was assessed using 
the NGI and the measurements were made at different times after manufacturing. The first result is 
from the measurements presented in 4.1, the second measurements were made approximately 3 
weeks after the first measurement and the third measurements was made approximately a month 
after that. No data from the 45 minute sample were acquired in the first measurement series. 
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4.4 Effect of intrinsic fines. 
When analyzing the lactose components of the formulations, it was unknown how much 
of an effect the intrinsic fines would have on the final performance. Therefore, lactose 
NGI analyses were made from the batches where no LF were added, i.e. the 8% BDP 
formulations. Both the coated and the standard batch were analyzed and two different 
mixing times (5 and 30 minutes) were chosen. The results are presented in Fig. 4.30.  
Regarding the coated formulations, the amount of LF is low for both samples, with a 
small decrease for the longer mixing time. For the standard formulations, the amount of 
LF seems to increase as the mixing time increases, indicating that LF are produced 
during mixing. A sample of pure carrier was also measured and the result lies within the 
same reach of the 5 minute samples. The difference might be within the error margins 
as the method of lactose analysis was flawless. 
 
 
Figure 4.30: A comparison of the intrinsic LF within 8% BDP formulations. The bars represent a 
mean value of 2 replicates and the error bars shows the standard deviation. 
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4.5 Images from scanning electron microscopy  
To further understand the structure and distribution of finer particles in the 
formulations, morphological images were acquired using scanning electron microscopy 
(SEM). The batches that were analyzed were the 4% BDP + 4% LF of both the coated and 
the standard formulations. The results can be seen in Fig. 4.31-4.33. Note that these 
images are not necessarily representative of the formulations as a whole, but more as a 
qualitative way of understanding the arrangement of particles. 
Coated formulations 
Fig. 4.31-4.33 shows the resulting SEM images for the coated formulation from samples 
of 10, 60 and 120 minutes of mixing. It can be seen that in the earlier mixing stages 
there are more particles or agglomerates on the carriers and for the 120 min sample 
there seems to be fewer particles or agglomerates on the carriers. A possible 
explanation to this is that the particles are either pressed onto the carriers or they might 
tumble off the carriers in the mixing progress. 
 
 
 
Figure 4.31: SEM images acquired from the 4% BPD + 4% LF for the coated formulation, taken at 10 
minutes of mixing. 
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Figure 4.32: SEM images acquired from the 4% BPD + 4% LF for the coated formulation, taken at 60 
minutes of mixing. 
 
Figure 4.33: SEM images acquired from the 4% BPD + 4% LF for the coated formulation, taken at 120 
minutes of mixing. 
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Standard formulations 
Fig. 4.34-4.35 shows the resulting SEM images for the standard formulation from 
samples of 10 and 60 minutes of mixing. One difference that can be observed is that in 
the beginning of the mixing there seems to be more particles/agglomerates coated on 
the carriers. 
 
Figure 4.34: SEM images acquired from the 4% BPD + 4% LF for the standard formulation, taken 
from 10 minutes of mixing 
 
Figure 4.35: Figure 4.31: SEM images acquired from the 4% BPD + 4% LF for the standard 
formulation, taken from 60 minutes of mixing 
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5. Discussion 
In the following chapter the results will be discussed and evaluated. The discussion will 
be divided into two main parts, where the first one will consider the observed 
dispersion properties of the formulations, with a main focus evaluating the data 
assessed from the NGI. The second part focuses on correlating data from NGI to that 
obtained by LD. 
5.1 Behavior of the adhesive mixtures 
This section will consider and discuss the nature and behavior of the manufactured 
formulations based on the obtained results from the NGI. The observed effects will be 
discussed one by one. It should be noted that previous research in this area can not 
necessarily be aligned to this study as there are many variables that can change the 
results. For example, this work used a rather simple dispersion device, where other 
studies employed more advanced inhalers. Furthermore, different APIs behave 
differently and it is not unlikely to believe that LF will behave in another way if mixed 
with other APIs. 
5.1.1 Effect of coating agent 
As described in chapter 1 the adhesive forces between carriers and excipients in an 
adhesive mixture can be reduced by introducing a so called coating agent. For this study 
MgSt was used and it is clear that it influences the dispersability of the powder greatly. 
Regarding the BDP, FPF is significantly higher for the coated formulations, see Fig. 5.1. 
The same goes for the LF, see Fig. 5.2, although this effect have not been shown before. 
This is in agreement with the stated theory described in section 1.1, that a FCA reduces 
adhesive forces within an adhesive mixture. Naturally, when the forces between 
particles are weakened the dispersability of the powder mixture increases, resulting in a 
higher FPF profile for the coated formulations. 
Another observation that can be made is that the mixing time is critical for coated 
formulations whereas the mixing time seems to be less important for standard 
formulations. The strong and non-linear influence of mixing time is alone an interesting 
observation and will be discussed in the subsequent section. 
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Figure 5.1: Comparison between the FPF profiles of the BDP component in 4% respective 8% 
concentration for coated and standard formulations. It is clear that the FPF of the coated 
formulations is consistently higher for all batches. 
 
Figure 5.2: Comparison between the FPF profiles of the LF component in 4% respective 8% 
concentration for coated and standard formulations. It is clear that the FPF of the coated 
formulations is consistently higher for all batches. 
 
5.1.2 Influence of different mixing times 
As mentioned in the previous section, the coated formulations display a rather critical 
impact from the mixing process, in terms of different mixing times. As regards the 
standard formulations no such clear effect can be seen. 
Starting with the BDP analysis, the appearance of the FPF curves, see section 4.1 or Fig 
5.1, displays an initial increase.  At a certain point the curve shifts and starts to decrease 
instead, as the mixing time go on. As this appearance is more or less absent for the 
standard formulations, it indicates that the coating of the carriers plays an important 
role within the process.  
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When preparing the manufacturing of the formulations, the raw material of BDP was 
introduced in the form of apparent agglomerates. These were then distributed in the 
powder mixture by a slow pre-mixing step. When the full speed of the mixing blades 
(800 rpm) was set, it is not unlikely to believe that these agglomerates started to break 
up into smaller parts due to the shear forces induced by the mixing blades along with 
collisions with the carriers.  
Such de-agglomeration has also been observed by Nguyen et al [19], which further 
fortifies this reasoning. As the size of the BDP agglomerates decreases, it is possible to 
that they start to adhere to the layer of MgSt on the carriers. Considering that the FPF 
increased as the mixing progressed, the BDP must somehow be able to disperse more 
easily upon inhalation.  
A possible explanation to this can be that the BDP (particles/agglomerates) are getting 
more and more evenly distributed onto the layer of MgSt on the carrier particles. As the 
MgSt works to reduce adhesive forces it is likely that a higher FPF is achieved when BDP 
and MgSt interact. This can be done either by the adhesion of BDP particles onto the 
coated carriers, or that the MgSt adheres to and lubricates the fine BDP particles.  
As the mixing goes on it is observed that at a certain point, the dispersibility of the 
powder is reduced. One explanation can be that the particles/agglomerates that have 
adhered to the carriers are getting more and more compressed into the carriers. At a 
certain time point, the rate of BDP (particles/agglomerates) adhering to the carriers is 
surpassed by the rate of BDP affected by these press-on forces, which results in the shift 
and decrease of the FPF curve. Another explanation could be that longer mixing might 
break down clusters of particles that are easily dispersed during inhalation, thus 
lowering the FPF profile. 
The rather flat FPF-profile achieved for the standard formulations shows that without 
the coating with MgSt, the BDP is less able to disperse from the carriers. This is expected 
as the carriers coated with MgSt have a lower surface energy and friction than the 
uncoated carrier [7]. Furthermore, the effect of different mixing time seems to be less 
crucial for the standard formulations. 
The reasoning above has yet to include the effect of the added LF. As goes for this 
component, the analysis is not as straight forward as for the case of BDP. The NGI data 
are given in FPF of total amount of lactose, not just FPF of the added LF. To be able to 
compare the FPF of BDP and added LF, a conversation of the FPF of lactose has to be 
made. This is simply done by dividing the FPF by the concentration of LF, see eq. 5.1. 
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                       ⁄
 (eq. 5.1) 
 
In Figure 5.3 - 5.5 this conversation has been done for coated formulations including 
both BDP and LF. As can be seen, the FPF of the LF is consistently higher than that of the 
BDP.  
The curvature for the BDP is almost the same for all formulations, with differing values 
in FPF. But, as goes for the FPF of LF, this is not the case. The formulation with the 
highest amount of LF, i.e. 6%, is showing a rather flat appearance at the start of the 
mixing process, but as the BDP reaches its maximum, so does the LF starts to decline. 
For the case of 4% BDP +4% LF, the LF curve is rather flat during the whole mixing 
process. For the 6% BDP + 2 % LF the LF seems to follow the BDP curve. However, if this 
is due to the formulations themselves or within the uncertainty of the measurement 
method is yet unknown. 
 
Figure 5.3: Fine Particle Fraction for coated formulation containing 6% LF and 2% BDP as a function 
of mixing time. 
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Figure 5.4 Fine Particle Fraction for coated formulation containing 4% LF and 4% BDP as a function 
of mixing time. 
 
 
Figure 5.5 Fine Particle Fraction for coated formulation containing 2% LF and 6% BDP as a function 
of mixing time. 
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5.1.2.1 Mathematical modeling of FPF of BDP 
To further understand the FPF behavior of the BDP, data can be fitted to a descriptive 
mathematical equation, from which for example rate constants for the process can be 
estimated. Based on the FPF profile versus mixing time of the BDP component for 
coated formulations, it is clear that that an initial increase is taking place (y1) followed 
by a decaying segment (y2). This can be described by two different equations, where the 
combination of the two gives the FPF, displayed in eq. 5.2- 5.4. 
 
      
 
        
  (eq. 5.2) 
 
     
       (eq. 5.3) 
 
            (eq. 5.4) 
 
A and B are constants relating to the FPF level, k1 and k2 are the rate-constants for the 
coating respective pressing, or “caking”, processes.  
Table 5.1: Calculated constants from equations 5.2-5.4 
 A B K1 [min-1] K2 [min-1] R2 
2% BDP 
 
-27.9 91.7 0.07 0.008 0.94 
4% BDP 
 
-43.4 115.5 0.05 0.009 0.94 
6% BDP 
 
-44.1 111.0 0.04 0.008 0.88 
8% BDP 
 
-45.7 108.5 0.04 0.010 0.90 
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Figure 5.6: Mathematical modeling for FPF values of coated formulations, as regards the BDP 
component. The dots represent the assessed data and the line represents values acquired from the 
equation. 
As can be seen in Fig 5.6, the mathematical model fits the FPF-values rather well, as 
displayed by the R2 values close to 1 given in table 5.1.  More data-points should 
possibly give a better fitting.  
However, the rate constants for the mathematical models were roughly the same for all 
formulations. k1 was consistently larger than k2, indicating that the coating step is faster 
than the caking process. For further understanding of the formulations it would be 
favourable if more time points could be obtained. The calculated constants can be seen 
in table 5.1. 
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5.1.3. Effect of different concentrations between BDP and LF 
When considering the relative concentration between BDP and LF it is quite obvious 
that LF have an influence on the FPF of BDP. A clear pattern is seen that the 
formulations with the lowest amount of BDP, and thus highest amount of LF, results in 
the highest FPF of BDP, see Fig. 5.7. This is somewhat contradictory to a previous study 
reviewed by Jones et al [3] which suggested that the optimum relationship between the 
API and LF should be 1:1. However, that study employed another type of API than the 
one used in this thesis as well as larger LF.  Even though those results cannot be directly 
compared with the results in this thesis, it displays the difficulties of studying adhesive 
mixtures as there are many different factors that can alter the results.  
In Fig. 5.7 the FPF for each formulation at 30 minutes of mixing is plotted against the 
concentration of BDP.  
 
Figure 5.7: How the FPF is affected by concentration of BDP, taken from 30 minutes into mixing 
process. The upper image displays coated formulations and the lower displays standard 
formulations. The values represent mean values of 2 replicates and the error bars shows the 
standard deviations. 
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This can be explained by the fact that LF gives a higher FPF than the BDP for all 
formulations. Amongst the theories proposed to explain the effect of LF is the formation 
of agglomerates. Assuming that this takes place during mixing, a co-agglomerate of BDP 
and LF will likely give a FPF value somewhere in between that of the FPF of LF and BDP 
separately.  This could also tell something about the adhesive forces interacting in such 
clusters; the more LF the less stable clusters, as an increased LF concentration gives a 
higher FPF. 
5.1.4 Formation of agglomerates  
As stated in previous section there are indications that the BDP and LF interact when 
mixed together. This would be in agreement with the theory stated in chapter 1 (that 
agglomerates of BDP and LF are built up during the mixing process). Regarding the 
MMAD values of BDP they are considerably larger than the size of a single particle, 
which supports the theory of formation of agglomerates. As a combination of BDP and 
LF resulted in a FPF value somewhere in between, it is likely to believe that co-
aggregates are forming during mixing. Another interpretation of the data is that 
including LF into the formulations forms larger clusters. If these clusters would be 
equally parted BDP as LF, the MMAD should show the same value, which is not the case.  
However, the MMAD evaluation of LF is not to be entirely relied on as the PSD includes 
the carriers, which may lead to a skewed distribution that the excel template cannot 
account for [5]. It is also seen (Figure 4.6) that the less BDP the higher MMAD for BDP, 
which is consistent with co-aggregate formation taking into account that LF have a 
larger particle size. 
An observation made from the FPmode results from Inhaler setup (Figure 4.24 and 4.25) 
is that there are agglomerates present in the beginning of the mixing stage, but as the 
air flow increases from 50 lpm to 100 lpm, the values of FPmode is decreased, indicating 
a breakage of these agglomerates. This must mean that there are agglomerates within 
the powder mixtures strong enough to withstand a flow of 50 lpm. When the flow 
increases it is enough to partially break down these clusters, resulting in lower FPmode. 
Not only being in agreement with the theory on formation of agglomerates , it would 
also give an indication on how strong the agglomerates are. 
When analyzing SEM images taken at different time points, it can be seen that in the 
beginning of the mixing process there are particles, or agglomerates, on the surfaces of 
the carriers.  
Even though these images only give a qualitative picture of the powders, it can be seen 
that at 10 and 60 minutes there are agglomerates or particles adhered to the carriers. 
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For the 120 minute sample the amount of agglomerates/clusters seems to be less, 
either because they have broken down, or have been pressed onto the carriers as a 
result of over mixing.  
5.2. Comparison between NGI and Laser Diffraction 
This section will be devoted to finding out how well the NGI data fits the data assessed 
by laser diffraction (LD). It has been observed in previous studies that the used 
instrument overestimates the amount of finer particles when analyzing adhesive 
mixtures [15]. To adjust for this overestimation a calibration curve can be generated. 
This can be done by measuring a known weight concentration of fines and carrier using 
the RODOS setup. As the RODOS setup disperses the powder mixture fully, each 
component is being analyzed separately. In a previous Master thesis [18] such 
calibration curve was generated using the same batch of LF and carrier as used in this 
work. A calibration curve was also acquired for an API referred to as AZD8683. With 
AZD8683 having the same density as BDP and a similar particle size distribution, it can 
be assumed that they will scatter the light similarly; therefore it is considered that this 
calibration curve can be used for BDP as well. The calibration curves, shown in Fig 5.8, 
give the relation for much of signal < 5 µm a certain amount of fines corresponds to. Eq. 
5.5 and 5.6 describes this overestimation effect: 
 
Figure 5.8: Calibration curves showing how much the Sympatec instruments overestimates the 
amount of particles <5 µm. The values represent mean values of 3 replicates. The horizontal error 
bars represents the standard deviation of the weight in amount. The vertical error bars represent the 
standard deviation from the measurement [18] 
                                           
    (eq. 5.5) 
 
                               
                     (eq. 5.6) 
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These equations can be used to transform the FPF data from NGI for both BDP and LF 
into values corresponding to LD measurements. 
It is assumed that the MgSt has little influence on the measurements regarding F5. This 
is believed to be valid because MgSt is seen to form a layer around the carriers, giving 
little contribution to the F5. As the MMAD analysis of the LF is rather inconclusive there 
is no point in trying to correlate MMAD assessed by the NGI with FPmode. As displayed 
in the RODOS setup (Fig. 4.18) a higher amount of BDP gives a higher F5. This can be 
explained by the fact that LF contains a part of particles larger than 5 µm which is not 
taken into account in the data-evalution of the instrument. 
As the air flow used in the NGI measurements (77 lpm) differed from the Inhaler setup 
(50 and 100 lpm) a mean value was taken from the inhaler data in order to see if that 
gave a better correlation.  
The comparison between the NGI and LD data will be done by extracting the coefficient 
of determination, denoted R2. It is a statistical coefficient that explains how much of 
the variability of a factor is caused or explained by its relationship to another factor. In 
Fig. 5.9 the translated NGI values are plotted on the x-axis and the LD data are plotted 
on the Y-axis. The responding R2 are rather close to 1, which should indicate a good 
correlation. In general, the higher the R2, the better the model fits the data. The R2 can 
have values between 0 and 1. For other plots such as Fig 5.9 see Appendix II. 
 
Figure 5.9: Correlation between Sympatec Inhaler and NGI for coated formulation containing 0% BDP 
and 8% added LF. The correlation is very good as R
2
 approaches 1. 
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In the following sections different plots will be given where the NGI data has been 
translated into corresponding LD values, starting with the coated formulations. 
Coated formulations 
The calculated R2 values for the coated formulations are displayed in table 5.2. It can be 
seen that formulations including only one type of added fines, i.e. 8 % BDP + 0% LF and 
0% BDP + 8% LF, shows highest R2 values. However, the values assessed by the Inhaler 
setup had a rather high relative standard deviation (RSD) between replicates, inducing 
an uncertainty into the correlations. 
Table 5.2: R2 for correlation between NGI and LD data, for the 1% MgSt coated formulations. 
Formulation R2 , 50 lpm R2 ,  100 lpm R2 ,  Mean 
8% BDP + 0% LF + 1% MgSt 
 
0.46 0.79 0.93 
6% BDP + 2% LF + 1% MgSt 
 
0.19 0.01 0.05 
4% BDP + 4% LF + 1% MgSt 
 
0.87 0.05 0.56 
2% BDP + 6% LF + 1% MgSt 
 
0.00 0.73 0.84 
0% BDP + 8% LF + 1% MgSt 
 
0.93 0.97 0.94 
 
 
By instead plotting the values as a function of mixing time, the behavior of each 
formulation can be investigated. This is done in Fig. 5.10 and 5.11.  
Starting with Fig. 5.10 with the formulation containing 8 % BDP, 0% LF and 1% MgSt, the 
100 lpm and NGI data seems to have similar curvature (R2 = 0.79, see table 5.2) whereas 
the 50 lpm data does not follow the NGI data at all. The formulation containing 8% LF at 
the air flow of 50 gives a rather similar curve to the translated NGI data, as well for 100 
lpm (R2 = 0.93 and R2=0.97, respectively). 
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Figure 5.10: Comparison between Sympatec Inhaler and NGI for formulations containing 8% BDP + 
0% LF and 0% BDP + 8%LF.  
When continuing with the rest of the coated formulations there are both bad and good 
correlation results, as seen in table 5.2. It seems that the higher amount of BDP, the 
worse is the correlation. In Fig 5.11, the formulation with 6% BDP and 2 % LF displays 
both rather poor correlation as well as poor curve-fitting as the R2 values are close to 0. 
However, even though the correlations are rather bad the curvatures are in some cases 
very alike. For example, the mean value curvature for formulation 4% BDP + 4% LF is 
almost the same as the NGI data, even if R2 = 0.56. This shows that behavior of a 
formulation can be predicted by the usage of LD and that the poor correlation value is 
just due to the very flat curves. 
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Figure 5.11: Comparison between Sympatec Inhaler and NGI for formulations containing 6% BDP + 
2% LF,  4% BDP + 4%LF and 2% BDP + 6% LF.  
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Standard Formulations 
As for the standard formulations, the batch with only lactose correlates really well, as displayed 
by the R2 values shown in table 5.3. However, for formulations with added BDP the correlations 
are worse (highest R2=0.46), indicating that the BDP is more cohesive than lactose and that the 
dispersion of BDP is more dependent on the setup than lactose. 
Table 5.3: R2 for correlation between NGI and LD data, for the standard formulations. 
Formulation R2 , 50 lpm R2 ,  100 lpm R2 ,  Mean 
8% BDP + 0% LF 
 
0.11 0.16 0.23 
4% BDP + 4% LF 
 
0.46 0.21 0.36 
0% BDP + 8% LF 0.93 0.95 0.92 
 
As can be seen in Fig. 5.12 the appearance of the curves are rather flat, which make a 
comparison between NGI and LD rather inconclusive 
To conclude this section it is clear that the formulations with both LF and BDP show a poorer 
correlation between LD and NGI than formulations with only one component of fines. But, even 
if the R2 sometime is rather poor the appearance of the curves can be very similar, indicating 
that it is possible to screen a formulation using LD. 
However, the calibration curve used was made for another API with another PSD than the BDP. 
To further investigate if there is a possible way of screening formulations using these LD setups, 
a calibration curve originating from BDP should be made as well as applying more similarly 
dispersion setups, as regards the flow used as well as the dispersion devices. Optimum would be 
if the same device could be used in both setups as it seems that the formulations are rather 
dependent on the exact dispersion conditions and  settings that are used. 
To be able to correct for the contribution from the LF in a screening of a formulation, the 
analysis of lactose in the NGI needs to be better understood. Further investigations are needed 
to see if the LF behaves in the same way as here reported or differently, when combined with 
another API. The more knowledge gained about the behavior of LF, the easier it will be to 
correct for it in LD measurements. 
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Figure 5.12: Comparison between Sympatec Inhaler and NGI for formulations containing 6% BDP + 
2% LF,  4% BDP + 4%LF and 2% BDP + 6% LF.  
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6. Conclusions and further work. 
The following chapter will give a conclusion of this work, followed by suggestions on 
what can be done in future studies. 
6.1 Conclusions 
In this thesis, adhesive mixtures intended for inhalation were manufactured using a high 
shear mixer. Two different sets of formulations were produced, one with the addition of 
a coating agent, MgSt, and the other without such component. Lactose monohydrate 
was used as carrier. The API used was BDP, a glucocorticoid with anti-inflammatory 
properties. Furthermore, fine particle lactose were added and the total amount of 
added fines was kept constant, at 8 wt%, for all batches, whereas the relative weight 
concentration between lactose fines and BDP was varied systematically. Several samples 
were taken throughout the mixing process at different time points. 
To assess the particle size distribution of the manufactured batches, two different 
measurement techniques were used, first one was the NGI and the other being based 
on laser diffraction.  
NGI was used to assess the FPF and MMAD of BDP and LF. The analysis of BDP is rather 
straight forwards, but the analysis of LF needs more tuning and evaluation to be as fully 
reliable. For the manufactured formulations it was found that: 
 MgSt significantly increases FPF 
 Mixing time is critical for MgSt formulations 
 Initial increase in FPF  
 Overmixing reduces FPF  
 Mixing time is less important for standard formulations 
 LF yields higher FPF than BDP 
 LF and BDP interact with each other, possibly forming agglomerates which would 
lie in agreement with the suggested theory found in literature. 
 
The second part of this thesis was to see how well the data assessed from the NGI fitted 
with the data from the LD. A comparison between NGI and LD was done, where the 
obtained FPF of both BDP and LF was translated into corresponding values of the LD 
measurement system. It was found that: 
 Formulations with only LF shows best correlation 
 Coated formulations correlates better than standard formulations 
 Poor correlation does not mean poor fitting. 
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 Possible to correct for LF, but correlation depends on flow and setup of the two 
systems. 
 
6.2 Further work 
This thesis has approached the behaviour of LF within an adhesive mixture by 
manufacturing several formulations with varying concentration between LF and API. 
One of the conclusions drawn from the data was that the BDP and LF interact with each 
other, possibly forming agglomerates. To further strengthen this reasoning it would be 
favourable if the surface structure of the powder could be established more thoroughly 
than by SEM analysis. One technique that could be used for this purpose is Time Of 
Flight – Secondary Ion Mass Spectroscopy (TOF-SIMS).  
To further address the behaviour of LF the analysis method used for lactose is in need of 
improvement, to be as reproducible as the BDP method. It would be favourable if the 
influences of the carriers could be reduced, as a single bounce between impactor stages 
could drastically change the measurement data.  Optimum would have been to be able 
to use some sort if internal standard, e.g. glucose or an isotope of lactose, depending on 
the measurement technique. The LC-PAD method should be investigated further 
alongside with the MS to further improve the quality of data. 
As regards the correlation between NGI and laser diffraction data, the curvature of the 
translated data seems to fit LD data rather well.  As the LF seems to behave rather 
differently in different formulations, it will be hard to establish a general method to 
correct for LF in LD measurements. However, it would be favourable if the dispersion 
settings would be more similar. In the NGI the sample was sucked out from the 
dispersion device, whereas in the LD it was flushed out. It would also be favourable if 
the applied air flow was the same for both instruments as it has been shown that the 
dispersion is rather dependent on the airflow used. Another thing to do is to measure 
another calibration curve, based on BDP instead of AZD8684.  
To get a broader understanding of the behaviour of the lactose fines there are several 
other things that can be addressed. This thesis has investigated how the LF interact with 
a specific type of API. It is however not obvious how it will behave together with another 
type of API. It can also be investigated how the particle size of the LF will effect the 
system, as previous studies has indicated that this matters as well as the total 
concentration of finer particles and relative concentration between API/LF. 
Other type of investigations that can be made is to manufacture using another type of 
mixer process, for example a tumbler mixer which will give a more gentle mixing 
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process. The high shear mixer is a rather intensive process and the LF might interact and 
mix differently if subjected to another type of mixing. 
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Appendix I – Raw data from measurements 
Data from NGI 
 
Table A. Raw data from NGI measurements of 8% BDP + 0% LF. 
8% BDP + 0% LF 
  Coated with 1% MgSt Standard 
  BDP LF BDP LF 
min  FPF MMAD FPF MMAD FPF MMAD FPF MMAD 
5 Mean 26,9 2,58 - - 3,8 4,7 v - 
 SD 1,2 0,1 - - 0,0 0,1 - - 
10 Mean 29,2 2,44 - - 3,9 4,7 - - 
 SD 2,4 0,0 - - 0,2 0,2 - - 
20 Mean 39,1 2,23 - - 3,9 4,9 - - 
 SD 1,0 0,0 - - 0,1 0,0 - - 
30 Mean 43,3 2,15 - - 4,0 4,6 - - 
 SD 0,8 0,0 - - - - - - 
45 Mean - - - - - - - - 
 SD - - - - - - - - 
60 Mean 35,6 2,32 - - 5,5 4,1 - - 
 SD 1,3 0,0 - - 0,6 0,2 - - 
90 Mean - - - - - - - - 
 SD - - - - - - - - 
120 Mean 22,5 3,09 - - 4,5 4,5 - - 
 SD 0,1 0,0 - - 0,1 0,1 - - 
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Table B. Raw data from NGI measurements of 6% BDP + 2% LF. 
6% BDP + 2% LF 
  Coated with 1% MgSt Standard 
  BDP LF BDP LF 
min  FPF MMAD FPF MMAD FPF MMAD FPF MMAD 
5 Mean 26,9 2,58 0,99 4,34 - - - - 
 SD 1,2 0,1 - - - - - - 
10 Mean 29,2 2,44 1,04 4,59 - - - - 
 SD 2,4 0,0 - - - - - - 
20 Mean 39,1 2,23 1,05 4,35 - - - - 
 SD 1,0 0,0 - - - - - - 
30 Mean 43,3 2,15 1,19 6,11 - - - - 
 SD 0,8 0,0 - - - - - - 
45 Mean - - 0,94 7,43 - - - - 
 SD - - - - - - - - 
60 Mean 35,6 2,32 1,08 12,15 - - - - 
 SD 1,3 0,0 - - - - - - 
90 Mean - - 0,99 28,23 - - - - 
 SD - - - - - - - - 
120 Mean 22,5 3,09 0,89 10,28 - - - - 
 SD 0,1 0,0 - - - - - - 
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Table C. Raw data from NGI measurements of 4% BDP + 4% LF. 
4% BDP + 4% LF 
  Coated with 1% MgSt Standard 
  BDP LF BDP LF 
min  FPF MMAD FPF MMAD FPF MMAD FPF MMAD 
5 Mean 21,2 2,8 2,23 3,90 8,3 4,3 3,3 6,0 
 SD 0,2 0,1 - - 1,0 0,1 0,1 0,1 
10 Mean 26,1 2,7 2,18 4,34 8,3 4,2 2,8 6,6 
 SD 0,2 0,0 - - 0,2 0,2 0,1 0,2 
20 Mean 30,9 2,4 2,24 4,10 9,3 4,2 2,4 8,7 
 SD 0,0 0,0 - - 0,1 0,0 0,1 3,1 
30 Mean 40,3 2,2 2,22 4,59 9,0 4,3 1,9 7,5 
 SD 1,6 0,2 - - 0,5 0,0 0,1 0,3 
45 Mean - - 2,18 6,09 - - - - 
 SD - - - - - - - - 
60 Mean 36,7 2,4 2,22 4,84 8,4 4,4 1,8 8,4 
 SD 0,2 0,0 - - 0,3 0,0 0,1 2,0 
90 Mean - - 2,15 6,89 - - - - 
 SD - - - - - - - - 
120 Mean 26,0 3,1 2,19 5,13 7,9 4,8 - - 
 SD 3,0 0,1 - - 0,0 0,2 - - 
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Table D. Raw data from NGI measurements of 2% BDP + 6% LF. 
2% BDP + 6% LF 
  Coated with 1% MgSt Standard 
  BDP LF BDP LF 
min  FPF MMAD FPF MMAD FPF MMAD FPF MMAD 
5 Mean 26,9 2,58 3,42 4,25 - - - - 
 SD 1,2 0,1 - - - - - - 
10 Mean 29,2 2,44 3,38 5,78 - - - - 
 SD 2,4 0,0 - - - - - - 
20 Mean 39,1 2,23 3,46 4,29 - - - - 
 SD 1,0 0,0 - - - - - - 
30 Mean 43,3 2,15 3,41 4,84 - - - - 
 SD 0,8 0,0 - - - - - - 
45 Mean - - 3,75 5,19 - - - - 
 SD - - - - - - - - 
60 Mean 35,6 2,32 3,36 5,45 - - - - 
 SD 1,3 0,0 - - - - - - 
90 Mean - - 2,42 5,97 - - - - 
 SD - - - - - - - - 
120 Mean 22,5 3,09 2,36 5,93 - - - - 
 SD 0,1 0,0 - - - - - - 
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Table E. Raw data from NGI measurements of 0% BDP + 8% LF. 
0% BDP + 8% LF 
  Coated with 1% MgSt Standard 
  BDP LF BDP LF 
min  FPF MMAD FPF MMAD FPF MMAD FPF MMAD 
5 Mean - - 4,35 4,26 - - 3,3 6,0 
 SD - - - - - - 0,1 0,1 
10 Mean - - 3,94 4,63 - - 2,8 6,6 
 SD - - - - - - 0,1 0,2 
20 Mean - - 3,80 4,31 - - 2,4 8,7 
 SD - - - - - - 0,1 3,1 
30 Mean - - 3,62 4,88 - - 1,9 7,5 
 SD - - - - - - 0,1 0,3 
45 Mean - - 3,22 6,56 - - - - 
 SD - - - - - - - - 
60 Mean - - 2,80 6,52 - - 1,8 8,4 
 SD - - - - - - 0,1 2,0 
90 Mean - - 2,32 5,61 - - - - 
 SD - - - - - - - - 
120 Mean - - 3,05 5,97 - - - - 
 SD - - - - - - - - 
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Data from Sympatec inhaler - coated formulations 
 
Table F. Raw data from Sympatec inhaler measurements of 0% BDP + 8% LF. 
 
 0% BDP + 8% LF + 1% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 6,09 0,30 4,90 5,3 8,31 0,81 9,70 3,75 
5 5,19 0,43 8,26 6,3 7,58 0,30 3,96 3,8 
10 5,72 0,26 4,59 6,25 9,17 1,09 11,85 4,1 
20 5,81 0,27 4,64 5,85 10,06 0,96 9,51 3,85 
30 6,62 0,14 2,18 5,2 11,04 0,94 8,55 3,95 
45 6,55 0,22 3,29 4,85 11,35 0,71 6,23 3,75 
60 6,51 0,59 9,11 4,3 12,50 1,26 10,10 3,575 
90 7,12 0,46 6,41 4,25 13,51 1,24 9,15 3,5 
120 7,60 0,56 7,40 4,3 12,75 0,92 7,20 3,6 
 
Table G. Raw data from Sympatec inhaler measurements of 2% BDP + 6% LF. 
 
 2% BDP + 6% LF + 1% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 5,38 0,46 8,56 6,25 8,71 0,55 6,28 4 
5 5,95 0,33 5,53 7,2 8,35 0,37 4,48 4,5 
10 6,38 0,25 3,84 7,75 11,30 1,46 12,92 4,24 
20 5,61 0,58 10,37 7 11,20 0,80 7,18 4 
30 5,58 0,39 7,00 5,8 11,80 0,40 3,35 3,7 
45 5,03 0,38 7,56 4,3 13,12 1,05 7,97 3,6 
60 4,17 0,12 2,87 4,1 11,46 0,54 4,70 3,5 
90 3,96 0,43 10,90 4,3 12,88 1,29 10,02 3,6 
120 4,29 0,23 5,43 4,55 12,28 0,39 3,17 3,9 
 
Table H. Raw data from Sympatec inhaler measurements of 4% BDP + 4% LF. 
 
 4% BDP + 4% LF + 1% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 5,58 0,37 6,59 6,6 9,01 0,55 6,12 4,4 
5 5,53 0,33 6,01 7,6 9,01 0,52 5,76 4,68 
10 6,51 0,15 2,34 8,7 10,06 0,31 3,09 4,75 
20 6,68 0,22 3,33 7,8 12,17 1,66 13,63 4,35 
30 6,21 1,01 16,19 7,75 12,59 1,05 8,36 4 
45 5,35 0,56 10,47 4,3 11,94 1,30 10,89 3,5 
60 4,61 0,53 11,46 4 11,88 1,41 11,90 3,3 
90 4,49 0,50 11,04 4,3 10,52 0,52 4,97 3,64 
120 4,82 0,55 11,43 4,5 10,72 1,19 11,14 3,85 
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Table I. Raw data from Sympatec inhaler measurements of 2% BDP + 6% LF. 
 
 6% BDP + 2% LF + 1% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 5,70 0,18 3,19 7,25 8,18 0,24 2,99 3,35 
5 5,57 0,31 5,57 9,25 8,82 0,46 5,19 4 
10 6,66 0,27 4,09 8,5 9,69 0,61 6,31 4,1 
20 6,44 0,34 5,25 8,5 9,88 0,55 5,57 3,5 
30 6,55 0,62 9,48 7,5 10,80 1,02 9,45 3,1 
45 6,71 0,44 6,53 6 10,66 0,65 6,11 3,1 
60 5,70 0,60 10,46 4,2 10,54 0,68 6,42 3 
90 6,33 0,30 4,75 4,2 10,25 0,41 4,02 3,3 
120 6,71 0,31 4,55 4,6 9,66 0,63 6,56 3,5 
 
 
Table J. Raw data from Sympatec inhaler measurements of 0% BDP + 8% LF. 
 
 
 
8% BDP + 0% LF + 1% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 5,48 0,16 2,98 4,05 8,24 0,49 5,99 2,7 
5 5,68 0,44 7,66 4,35 8,75 1,00 11,46 2,85 
10 5,63 0,13 2,23 4,7 10,00 0,97 9,70 2,85 
20 5,77 0,21 3,72 5 10,75 0,92 8,55 2,8 
30 4,95 0,31 6,22 5,5 10,64 1,07 10,09 2,75 
45 4,87 0,36 7,38 4,7 10,12 0,66 6,54 2,72 
60 3,92 0,28 7,02 3,6 9,08 0,49 5,41 2,52 
90 3,70 0,23 6,27 3,8 8,37 1,07 12,81 3 
120 4,34 0,11 2,48 4,1 9,18 0,85 9,28 3,2 
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Data from Sympatec inhaler - standard formulations 
 
Table K. Raw data from Sympatec inhaler measurements of 0% BDP + 8% LF. 
 
 0% BDP + 8% LF +0% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 2,95 0,09 3,17 9 6,79 0,77 11,33 6,1 
5 3,02 0,22 7,23 8,5 5,60 0,32 5,72 6,1 
10 2,93 0,05 1,84 7,8 6,14 0,87 14,13 5,9 
20 3,20 0,12 3,65 7,5 6,78 0,52 7,61 5,81 
30 3,29 0,18 5,49 7,8 7,19 1,24 17,21 5,9 
45 3,81 0,38 9,90 7,9 7,75 0,64 8,28 6,05 
60 3,91 0,40 10,27 7,95 9,11 1,02 11,24 6,05 
90 3,87 0,31 7,98 7,75 9,35 0,68 7,28 5,95 
120 2,95 0,09 3,17 9 6,79 0,77 11,33 6,1 
 
Table L. Raw data from Sympatec inhaler measurements of 4% BDP + 4% LF. 
 
 4% BDP + 4% LF +0% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 1,93 0,14 7,45 10,68 3,87 0,19 4,84 7 
5 1,86 0,08 4,55 10,5 4,31 0,43 9,93 7,2 
10 2,00 0,07 3,68 10,5 4,58 0,23 5,12 7 
20 1,99 0,10 4,93 10,7 4,95 0,28 5,58 6,9 
30 2,03 0,09 4,38 11,45 4,60 0,13 2,72 6,7 
45 1,95 0,10 5,35 9 4,90 0,17 3,39 6,5 
60 1,83 0,04 2,13 9 4,71 0,32 6,83 6,45 
90 1,87 0,10 5,30 9,2 4,93 0,36 7,27 6,55 
120 2,10 0,10 4,70 9,6 5,72 0,37 6,42 6,65 
 
Table M. Raw data from Sympatec inhaler measurements of 8% BDP + 0% LF. 
 
 8% BDP + 0% LF +0% MgSt  
Inhaler - 50 lpm Inhaler – 100 lpm 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 0,90 0,03 3,02 - 2,33 0,08 3,27 - 
5 0,76 0,03 4,36 - 2,14 0,05 2,26 - 
10 0,79 0,03 4,04 - 2,28 0,13 5,72 - 
20 0,82 0,04 5,17 - 2,28 0,10 4,32 - 
30 0,84 0,06 7,15 - 2,27 0,05 2,00 - 
45 0,84 0,06 6,67 - 2,25 0,05 2,05 - 
60 0,85 0,05 6,28 - 2,48 0,13 5,12 - 
90 0,82 0,03 4,27 - 2,50 0,16 6,32 - 
120 0,99 0,08 8,10 - 3,25 0,16 5,08 - 
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Data from Sympatec RODOS – 4 bar 
 
Table N. Raw data from Sympatec RODOS measurements of 0% BDP + 8% LF. 
 
 0% BDP + 8% LF   
Coated with 1% MgSt Standard 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 12,65 0,76 6,00 2,2 17,13 1,00 5,84 2,46 
5 11,01 0,37 3,37 2,2 16,80 0,84 5,03 2,46 
10 11,55 0,46 3,95 2,25 15,82 0,16 1,03 2,46 
20 11,79 0,19 1,61 2,35 14,50 1,40 9,66 2,45 
30 13,78 0,53 3,83 2,45 13,28 0,15 1,13 2,6 
45 14,67 0,30 2,06 2,4 15,41 0,27 1,72 2,7 
60 15,97 0,07 0,44 2,3 16,42 0,61 3,73 2,85 
90 16,98 0,26 1,53 2,4 16,33 0,33 2,02 2,95 
120 17,52 0,45 2,58 2,2 17,13 1,00 5,84 2,46 
 
Table O. Raw data from Sympatec RODOS measurements of 2% BDP + 6% LF. 
 
 2% BDP + 6% LF   
Coated with 1% MgSt Standard 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 12,93 0,19 1,49 1,8 - - - - 
5 11,98 0,12 1,03 1,7 - - - - 
10 14,54 0,14 0,99 1,5 - - - - 
20 16,13 0,15 0,95 1,4 - - - - 
30 17,43 0,15 0,87 1,5 - - - - 
45 19,59 1,28 6,52 1,7 - - - - 
60 18,83 0,24 1,29 1,85 - - - - 
90 19,27 0,22 1,12 2,2 - - - - 
120 18,62 0,38 2,02 2,4 - - - - 
 
Table P. Raw data from Sympatec RODOS measurements of 4% BDP + 4% LF. 
 
 4% BDP + 4% LF   
Coated with 1% MgSt Standard 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 12,63 0,17 1,37 1,3 14,20 0,39 2,75 1,75 
5 12,66 0,21 1,64 1,2 15,32 0,66 4,29 1,775 
10 15,43 0,11 0,69 1,17 18,08 0,57 3,16 1,76 
20 16,88 0,28 1,64 1,16 18,99 0,52 2,75 1,8 
30 18,79 0,18 0,94 1,15 20,16 0,84 4,15 1,8 
45 20,06 0,14 0,68 1,21 20,00 0,82 4,12 1,95 
60 20,55 0,16 0,80 1,3 18,59 1,04 5,61 2,2 
90 20,12 0,13 0,64 1,95 18,88 1,00 5,32 2,57 
120 20,02 0,41 2,04 2,15 18,40 0,31 1,70 2,73 
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Table Q. Raw data from Sympatec RODOS measurements of 6% BDP + 2% LF. 
 
 6% BDP + 2% LF   
Coated with 1% MgSt Standard 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 12,38 0,22 1,80 1,15 - - - - 
5 13,20 0,22 1,67 1,15 - - - - 
10 15,99 0,22 1,37 1,15 - - - - 
20 17,86 0,22 1,23 1,1 - - - - 
30 20,57 0,27 1,31 1,1 - - - - 
45 21,61 0,51 2,36 1,1 - - - - 
60 21,79 0,29 1,33 1,15 - - - - 
90 21,55 0,32 1,48 1,14 - - - - 
120 20,86 0,91 4,36 1,18 - - - - 
 
Table R. Raw data from Sympatec RODOS measurements of 8% BDP + 0% LF. 
 
 8% BDP + 0% LF   
Coated with 1% MgSt Standard 
Min F5 SD RSD FPmode F5 SD RSD FPmode 
2 12,76 0,19 1,46 1,1 13,87 1,67 12,03 1,2 
5 14,50 0,05 0,37 1,1 18,10 0,76 4,21 1,225 
10 17,04 0,27 1,59 0,95 18,61 1,22 6,58 1,195 
20 19,85 0,17 0,84 0,95 18,13 1,64 9,07 1,25 
30 21,98 0,28 1,27 0,9 17,35 0,39 2,27 1,225 
45 22,12 0,46 2,07 0,9 17,62 0,26 1,48 1,235 
60 23,49 0,42 1,80 0,95 19,23 0,38 1,96 1,185 
90 22,99 0,20 0,88 1,15 19,31 0,56 2,89 1,165 
120 21,84 1,09 5,00 1,3 19,49 1,02 5,26 1,23 
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Appendix II – Correlation plots 
 
Coated formulations 
 
Figure A: Correlation between Sympatec Inhaler and NGI for coated formulation containing 0% BDP 
and 8% added LF. 
 
Figure B: Correlation between Sympatec Inhaler and NGI for coated formulation containing 2% BDP 
and 6% added LF. 
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Figure C: Correlation between Sympatec Inhaler and NGI for coated formulation containing 4% BDP 
and 4% added LF. 
 
Figure D: Correlation between Sympatec Inhaler and NGI for coated formulation containing 6% BDP 
and 2% added LF. 
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Figure E: Correlation between Sympatec Inhaler and NGI for coated formulation containing 8% BDP 
and 0% added LF. 
Standard formulations 
 
Figure F: Correlation between Sympatec Inhaler and NGI for standard formulation containing 0% 
BDP and 8% added LF. 
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Figure G: Correlation between Sympatec Inhaler and NGI for standard formulation containing 4% 
BDP and 4% added LF. 
 
 
Figure H: Correlation between Sympatec Inhaler and NGI for standard formulation containing 8% 
BDP and 0% added LF. 
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